Tag Archives: Clean Rooms

May 2, 2007 — /MARKET WIRE/ — SUNNYVALE, CA — Maxim Integrated Products, Inc. announced that it has acquired a wafer fabrication facility in Irving, TX, from Atmel for approximately $38 million. The facility, located on approximately 39 acres, is comprised of approximately 622,000 square feet of cleanroom and office space. Approximately 60,000 square feet is currently cleanroom space with the capability of expanding to 100,000 square feet.

Vijay Ullal, group president at Maxim, commented, “This facility puts us in an excellent position for future capacity requirements. It is capable of 20,000 eight inch wafer starts per month with the capability of expanding to over 30,000 wafer starts per month. The scale and construction of this facility will enable Maxim to bring on line capacity down to the 0.18 micron node with low cost and short cycle time with high yields.”

Maxim Integrated Products is a leading international supplier of quality analog and mixed-signal products for applications that require real-world signal processing.

Source: Maxim Integrated Products

Investment Community Contact:
Paresh Maniar
(408) 470-5348

Pharmatec GmbH: roughly 30 million euros sales and 160 associates

May 2, 2007 — STUTTGART, GERMANY — The Bosch Group plans to acquire Pharmatec GmbH, headquartered in Dresden, Germany, from Fresenius ProServe GmbH. The transaction also includes the acquisition of the Pharmatec subsidiary Schoeller-Bleckmann Medizintechnik Ges.m.b.H, headquartered in Ternitz, Austria. Pharmatec is a leading company in the construction of systems and lines for the pharmaceutical industry. Its focus is on hygienic and aseptic process technologies, especially for the pharmaceuticals and biotechnology fields.

In fiscal 2006, Pharmatec GmbH and its roughly 160 associates generated sales of some 30 million euros. “Pharmatec and Schoeller-Bleckmann Medizintechnik are both recognized specialists that excellently complement our existing product portfolio in the area of packaging technology for the pharmaceuticals industry,” said Friedbert Klefenz, president of the Bosch Packaging Technology division. It has been agreed that the purchase price will not be disclosed. The transaction is subject to approval by the antitrust authorities.

In the area of packaging technology, Bosch develops, manufactures, and markets process and packaging machinery and lines for the confectionery, foodstuffs, and pharmaceuticals industries. In 2006, the division generated global sales of some 570 million euros with a workforce of roughly 3,780 associates.

The Bosch Group is a leading global supplier of technology and services. In the areas of automotive and industrial technology, consumer goods, and building technology, some 260,000 associates generated sales of 43.7 billion euros in fiscal 2006. The Bosch Group comprises Robert Bosch GmbH and its roughly 300 subsidiary and regional companies in over 50 countries. This worldwide development, manufacturing, and sales network is the foundation for further growth. Bosch spends more than three billion euros each year for research and development, and in 2006 applied for over 3,000 patents worldwide. The company was set up in Stuttgart in 1886 by Robert Bosch (1861-1942) as “Workshop for Precision Mechanics and Electrical Engineering.”

Company expects to submit Devens site for regulatory approval in 2010

May 2, 2007 /PRNewswire-FirstCall/ — DEVENS, MA — Bristol-Myers Squibb Company executives were joined by Governor Deval Patrick, state and local officials, community leaders and MassDevelopment today for a groundbreaking ceremony at the site of the company’s new biologics manufacturing facility in Devens, MA. The company announced the selection of Devens in June 2006 and recently began construction at the site.

“The commitment to build this facility represents the single largest capital investment in the history of Bristol-Myers Squibb, demonstrating the critical role we believe biologics will play in the future of our company,” said Jim Cornelius, chief executive officer, Bristol-Myers Squibb. “Building this facility provides additional manufacturing capacity to meet future patient need for our biologic therapies and helps position the company for long-term growth in this important area of medicine.”

Bristol-Myers Squibb has committed $750 million to fund the construction of the facility. The new large-scale multi-product bulk facility is modular in design in order to accommodate potential future expansion. Phase I of the project calls for the construction of four main buildings: a manufacturing structure that will house six 20,000-liter cell culture vessels and one purification train, a central utility building, an administrative/quality control building, and a warehouse/storage structure. The facility is projected to be operationally complete in 2009, and the company plans to submit the site for regulatory approval in 2010.

“This Bristol-Myers Squibb facility is an important milestone for the Commonwealth and reflects our continued leadership in biotechnology and the life sciences,” said Senator Edward M. Kennedy. “Its presence in Massachusetts will only boost our ability to attract high quality jobs in the future and remain at the cutting edge of biotechnology for years to come.”

Phase I of the facility will require a workforce of approximately 350 employees. It is anticipated that future expansion of the site, including several additional buildings, could lead to a total of 550 or more employees. Any expansion will depend on both the demand for Bristol-Myers Squibb biologic medicines and regulatory approval of investigational compounds.

The facility will support increased production capacity for ORENCIA(R) (abatacept), the company’s first internally discovered and developed biologic medicine, and also manufacture commercial quantities of compounds currently in development should those compounds receive regulatory approval. The company’s investigational biologic compounds include treatments for certain types of cancers and solid organ transplant rejection.

“Massachusetts has a unique combination of resources, including top-tier educational institutions, a business-friendly economic environment and great quality of life, which attract companies such as Bristol-Myers Squibb,” said Gov. Deval Patrick. “We are very pleased with the company’s decision to locate this facility in Massachusetts, and we look forward to continuing a very productive relationship.”

“We selected this site based on a number of factors, including the abundance of biotechnology knowledge, education and training in the Boston area that has created a large and well-qualified workforce,” said Carlo De Notaristefani, president of technical operations, Bristol-Myers Squibb. “We are excited about our future in Devens and becoming a part of the community.”

Bristol-Myers Squibb currently manufactures biologic compounds in a company-owned facility in Syracuse, New York, and finishes and packages biologic compounds in Manati, Puerto Rico. The Syracuse site will remain a key component of the company’s biologics strategy, serving as the center of excellence in process development and early product launch for the company’s biologic compounds. The Syracuse facility was not designed to accommodate large-scale commercial production. The Manati facility, which is also wholly- owned by the company, will continue to finish and package biologic compounds. In March 2006, the company announced a $200 million investment to expand this facility to accommodate increased filling and finishing needs. Bristol-Myers Squibb also has biologic manufacturing agreements with third-party partners Lonza Biologics, Inc. and Celltrion, Inc.

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

Source: Bristol-Myers Squibb Company

Contact:
Jeff Macdonald
+1-212-546-4824
+1-917-371-0940
[email protected]

Marilyn Tretler
+1-732-227-5756
[email protected]
Web site: http://www.bms.com/

Air Products also supplies specialty materials and equipment to new Austin site

May 1, 2007 — /PRNewswire/ — LEHIGH VALLEY, PA — Air Products today announced that its 450,000 standard cubic foot per hour (scf/hr) nitrogen generator at Samsung Austin Semiconductor’s new 300mm memory manufacturing facility in Austin, TX, is on-stream.

The new 300mm fab is expected to manufacture dynamic random access memory (DRAM) and/or flash memory chips for computers, cell phones, and DVD and MP3 players.

Besides nitrogen, Air Products will also supply bulk specialty gases to the DRAM facility as well as specialty gas and chemical equipment

“The diversity of Air Products’ product offering continues to position us as the go-to supplier to the global semiconductor industry,” said Corning Painter, vice president, eectronics, at Air Products. “Air Products is proud to be able to support Samsung’s growth in the US, just as we have done in Korea.”

Samsung currently operates a 200mm fab in Austin where a dedicated team of Air Products MEGASYS(R) technicians manage Samsung’s materials and equipment. Air Products also operates a 240,000 scf/hr nitrogen generator for the 200mm fab and supplies Samsung Austin Semiconductor with its liquid bulk gas requirements as well as specialty materials, delivery systems and bulk specialty gases and equipment.

About Air Products
Air Products serves customers in industrial, energy, technology and healthcare markets worldwide with a unique portfolio of atmospheric gases, process and specialty gases, performance materials, and equipment and services. Founded in 1940, Air Products has built leading positions in key growth markets such as semiconductor materials, refinery hydrogen, home healthcare services, natural gas liquefaction, and advanced coatings and adhesives. The company is recognized for its innovative culture, operational excellence and commitment to safety and the environment and is listed in the Dow Jones Sustainability and FTSE4Good Indices. The company has annual revenues of $9 billion, operations in over 40 countries, and over 20,000 employees around the globe. For more information, visit www.airproducts.com.

About Samsung
Samsung Electronics Co., Ltd. is a global leader in semiconductor, telecommunication, digital media and digital convergence technologies with 2006 parent company sales of US$63.4 billion and net income of US$8.5 billion. Employing approximately 138,000 people in 124 offices in 56 countries, the company consists of five main business units: Digital Media Business, LCD Business, Semiconductor Business, Telecommunication Network Business and Digital Appliance Business. Recognized as one of the fastest growing global brands, Samsung Electronics is a leading producer of digital TVs, memory chips, mobile phones and TFT-LCDs. For more information, please visit www.samsung.com.

Source: Air Products

Contact:
Nelson Squires
+1-610-481-7461
[email protected]

Web site: http://www.airproducts.com/

http://www.samsung.com/

May 2, 2007 — /PRNewswire-USNewswire/ — WASHINGTON, DC — Nine solutions to prevent health care errors that harm millions of people daily throughout the world were unveiled today by the World Health Organization’s (WHO) Collaborating Centre for Patient Safety Solutions. The nine Patient Safety Solutions are available for use by WHO Member States.

The Patient Safety Solutions address the issues of look-alike, sound-alike medication names; correct patient identification; hand-over communications; correct procedure at the correct body site; control of concentrated electrolyte solutions; medication accuracy; catheter and tubing mis- connections; needle reuse and injection device safety; and hand hygiene. The basic purpose of the solutions is to guide the re-design of care processes to prevent inevitable human errors from actually reaching patients.

In 2005, WHO designated The Joint Commission and Joint Commission International as its Collaborating Centre on Patient Safety Solutions. The Joint Commission International Center for Patient Safety operationalized this effort by identifying widespread problems and challenges to safe care, identifying promising solutions, and vetting them through an extensive field review process that garnered feedback from health care providers, practitioners, and other experts from more than 100 countries.

“Patient safety is now recognized as a priority by health systems around the world,” says Sir Liam Donaldson, chair of the Alliance, chief medical officer for England, and chief medical adviser for the Government of the United Kingdom of Great Britain and Northern Ireland. “The Patient Safety Solutions program of work is addressing several vital areas of risk to patients. Clear and succinct actions contained in the nine solutions have proved to be useful in reducing the unacceptably high numbers of medical injuries around the world.”

“These solutions offer to WHO Member States a major new resource to assist their hospitals in avoiding preventable deaths and injuries,” says Dennis S. O’Leary, M.D., president, The Joint Commission. “Countries around the world now face both the opportunity and the challenge to translate these solutions into tangible actions that actually save lives.”

“These Patient Safety Solutions were designed through a truly international collaborative effort, and represent what has been learned internationally about where, how and why certain adverse events occur,” says Karen H. Timmons, president and chief executive officer, Joint Commission International. “A critical component of their development has involved inclusion of input from patients and their families who have experienced preventable harm.”

The individual Patient Safety Solutions identify the following challenges and strategies:
— Look-Alike, Sound-Alike Medication Names –Confusing drug names is one of the most common causes of medication errors and is a worldwide concern. With tens of thousands of drugs currently on the market, the potential for error created by confusing brand or generic drug names and packaging is significant. The recommendations focus on using protocols to reduce risks and ensuring prescription legibility or the use of preprinted orders or electronic prescribing.

— Patient Identification — The widespread and continuing failures to correctly identify patients often leads to medication, transfusion and testing errors; wrong person procedures; and the discharge of infants to the wrong families. The recommendations place emphasis on methods for verifying patient identity, including patient involvement in this process; standardization of identification methods across hospitals in a health care system; and patient participation in this confirmation; and use of protocols for distinguishing the identity of patients with the same name.

— Communication During Patient Hand-Overs — Gaps in hand-over (or hand-off) communication between patient care units, and between and among care teams, can cause serious breakdowns in the continuity of care, inappropriate treatment, and potential harm for the patient. The recommendations for improving patient hand-overs include using protocols for communicating critical information; providing opportunities for practitioners to ask and resolve questions during the hand-over; and involving patients and families in the hand-over process.

— Performance of Correct Procedure at Correct Body Site — Considered totally preventable, cases of wrong procedure or wrong site surgery are largely the result of miscommunication and unavailable, or incorrect, information. A major contributing factor to these types of errors is the lack of a standardized preoperative process. The recommendations to prevent these types of errors rely on the conduct of a preoperative verification process; marking of the operative site by the practitioner who will do the procedure; and having the team involved in the procedure take a “time out” immediately before starting the procedure to confirm patient identity, procedure, and operative site.

— Control of Concentrated Electrolyte Solutions — While all drugs, biologics, vaccines and contrast media have a defined risk profile, concentrated electrolyte solutions that are used for injection are especially dangerous. The recommendations address standardization of the dosing, units of measure and terminology; and prevention of mix-ups of specific concentrated electrolyte solutions.

— Assuring Medication Accuracy at Transitions in Care — Medication errors occur most commonly at transitions. Medication reconciliation is a process designed to prevent medication errors at patient transition points. The recommendations address creation of the most complete and accurate list of all medications the patient is currently taking — also called the “home” medication list. comparison of the list against the admission, transfer and/or discharge orders when writing medication orders. and communication of the list to the next provider of care whenever the patient is transferred or discharged.

— Avoiding Catheter and Tubing Mis-Connections — The design of tubing, catheters, and syringes currently in use is such that it is possible to inadvertently cause patient harm through connecting the wrong syringes and tubing and then delivering medication or fluids through an unintended wrong route. The recommendations address the need for meticulous attention to detail when administering medications and feedings (i.e., the right route of administration), and when connecting devices to patients (i.e., using the right connection/tubing).

— Single Use of Injection Devices — One of the biggest global concerns is the spread of Human Immunodeficiency Virus (HIV), the Hepatitis B Virus (HBV), and the Hepatitis C Virus (HCV) because of the reuse of injection needles. The recommendations address the need for prohibitions on the reuse of needles at health care facilities; periodic training of practitioners and other health care workers regarding infection control principles; education of patients and families regarding transmission of blood borne pathogens; and safe needle disposal practices.

— Improved Hand Hygiene to Prevent Health Care-Associated Infection (HAI) — It is estimated that at any point in time more than 1.4 million people worldwide are suffering from infections acquired in hospitals. Effective hand hygiene is the primary preventive measure for avoiding this problem. The recommendations encourage the implementation of strategies that make alcohol-based hand-rubs readily available at points of patient care; access to a safe, continuous water supply at all taps/faucets; staff education on correct hand hygiene techniques; use of hand hygiene reminders in the workplace; and measurement of hand hygiene compliance through observational monitoring and other techniques.

The Patient Safety Solutions were developed with the assistance of an International Steering Committee of patient safety experts and patient representatives, as well as Regional Advisory Councils in Europe, the Middle East, and the Asia-Pacific region. A major international field review of the proposed solutions was also conducted to gather feedback from leading patient safety entities, accrediting bodies, ministries of health, international health professional organizations and practitioners, patients, and other experts.

For more information or to view the complete Patient Safety Solutions, please access http://www.jointcommissioninternational.org/solutions.

The World Alliance for Patient Safety is a WHO programme launched in 2004. The Alliance, chaired by Sir Liam Donaldson, Chief Medical Officer of the United Kingdom, addresses 10 major action areas:
— The Global Patient Safety Challenge will galvanize global commitment and action on a patient safety topic, which addresses a significant area of risk for all countries. In 2005-2006, the Global Patient Safety Challenge is focusing on health care-associated infection with the theme Clean Care is Safer Care. For 2007-2008, the Global Patient Safety Challenge will focus on the topic of safer surgery with the theme Safe Surgery Saves Lives.

— Patients for Patient Safety will ensure that the voice of patients is at the core of the patient safety movement worldwide.

— Reporting and learning will promote valid reporting, analytical and investigative tools and approaches that identify sources and causes of risks in ways that promote learning and preventative action.

— Taxonomy for Patient Safety will develop an internationally acceptable system for classifying patient safety information to promote more effective international learning.

— Research for patient safety will facilitate an international research agenda which supports the safer health care in all WHO member states.

— Safety Solutions will translate knowledge into practical solutions and disseminate these solutions internationally.

— Safety in Action will spread best practices for implementation of changes in organizational, team and clinical practices to improve patient safety.

— Technology and patient safety will focus on the opportunities to harness new technologies to improve patient safety.

— Care of acutely ill patients will identify key patient safety priorities for action in the care of seriously ill patients.

— Patient safety knowledge at your fingertips will work with Member States and partners to gather and share knowledge on patient safety developments globally in the form of a global report.

Further information on the work of the Alliance is available at http://www.who.int/patientsafety.

Founded in 1951, The Joint Commission seeks to continuously improve the safety and quality of care provided to the public through the provision of health care accreditation and related services that support performance improvement in health care organizations. The Joint Commission evaluates and accredits nearly 15,000 health care organizations and programs in the United States, including more than 8,000 hospitals and home care organizations, and more than 6,300 other health care organizations that provide long term care, assisted living, behavioral health care, laboratory and ambulatory care services. The Joint Commission also accredits health plans, integrated delivery networks, and other managed care entities. In addition, The Joint Commission provides certification of disease-specific care programs, primary stroke centers, and health care staffing services. An independent, not-for- profit organization, The Joint Commission is the nation’s oldest and largest standards-setting and accrediting body in health care. Learn more about The Joint Commission at http://www.jointcommission.org/.

Joint Commission International (JCI) was established in 1997 as a division of Joint Commission Resources, Inc. (JCR), a private, not-for-profit affiliate of The Joint Commission. Through international accreditation, consultation, publications and education programs, JCI extends The Joint Commission’s mission worldwide by helping to improve the quality of patient care by assisting international health care organizations, public health agencies, health ministries and others evaluate, improve and demonstrate the quality of patient care and enhance patient safety in more than 60 countries.

Source: The Joint Commission

Contact:
Charlene D. Hill, ABC, The Joint Commission
+1-630-792-5175
[email protected];
or Agnes Leotsakos
WHO
+41 (22) 791 2567
[email protected]

Web site: http://www.jointcommission.org/

http://www.who.int/patientsafety

April 30, 2007 — BOURNE, MA — Onset Computer Corporation, a leader in battery-powered data loggers, today announced the availability of a new white paper entitled “Evaluating and Applying Data Loggers for Pharmaceutical Monitoring.”

The white paper provides quality assurance managers, regulatory compliance specialists, facility managers, and others with valuable tips on evaluating data loggers for pharmaceutical monitoring. It discusses how portable data loggers can be used in a broad range of projects, from analyzing temperatures in incubation chambers to monitoring storage and shipping conditions.

The white paper can be downloaded for free at http://www.onsetcomp.com.

About Onset Computer Corp.
Onset Computer Corporation has been producing small, inexpensive, battery-powered data loggers and embedded controllers since 1981, and has sold over 1,000,000 loggers that are used throughout the world by over 50,000 customers. The company manufactures a broad range of data logger and weather station products that are used to measure temperature, humidity, light intensity, voltage, and a broad range of other parameters.

Onset products are used in a wide range of research, commercial, industrial, and educational applications.

Contact:
Onset Computer Corporation
1-800-564-4377 / 508-759-9500
Fax: 508-759-9100
[email protected]

FDA News
Consumer Inquiries: 888-INFO-FDA

April 26, 2007 — /FDA News/ — The U.S. Food and Drug Administration (FDA) announced the entry of a Consent Decree of Permanent Injunction against PharmaFab Inc., its subsidiary, PFab LP, and two company officials, Mark Tengler, PharmaFab’s president, and Russ McMahen, PFab’s vice president of scientific affairs, to stop the illegal manufacture and distribution of prescription and over-the-counter drug products. The products are illegal because they are not produced according to the required current good manufacturing practice (cGMP) and many also lack required FDA approval. The case was filed in the United States District Court for the Northern District of Texas.

“Drug approval and CGMP compliance are part of the foundation of drug safety,” said Steven K. Galson, M.D., M.P.H, director of FDA’s Center for Drug Evaluation and Research (CDER). “When companies and individuals choose not to comply with the law, FDA must deal with these problems decisively.”

PharmaFab is a major contract manufacturer and distributor of more than 100 different prescription and over-the-counter drug products, including cough and cold products, ulcer treatments, and postpartum hemorrhage products. Consumers who have products manufactured by PharmaFab should consult with their physician.

The unapproved drugs manufactured by PharmaFab include, but are not limited to:

  • De-Congestine Sustained Release Capsules;
  • GFN 1200/DM 60/PSE 60 Extended-Release Tablets;
  • Rhinacon A Tablets;
  • Sudal 12 Chewable Tablets;
  • Histex PD 12 Suspension;
  • Atuss HX CIII;
  • Ergotrate Tablets; and
  • Hyoscyamine Sulfate Time-Release Capsules.

    Because these drugs have not undergone FDA approval, their safety and effectiveness have not been established, and FDA has not reviewed the adequacy and accuracy of the directions and warnings in their labeling.

    According to the complaint filed with the court, PharmaFab did not comply with cGMP by not investigating manufacturing failures and not recording and justifying why it deviated from written manufacturing procedures. Further, the company lacked an effective quality control unit and failed to establish reliable expiration dates for products. Compliance with cGMP is necessary to ensure that drugs have the requisite safety, identity, strength, quality, and purity.

    The consent decree requires the defendants to destroy certain illegal drugs, and bars them from distributing all drugs until they obtain required FDA approval and fully comply with cGMP. If they resume distributing drugs, the defendants are required to retain an auditor to conduct inspections of their facilities for a period of five years and to provide reports to FDA analyzing compliance with cGMP and labeling requirements. The decree also allows FDA to require recall or shutdown in the event of future violations and provides for damages of $5,000 per day and $1,000 per violation, up to a maximum of $5 million per year, if the defendants fail to comply with its terms.

    “FDA will not hesitate to pursue enforcement action when necessary,” said Margaret O’K. Glavin, FDA’s associate commissioner for regulatory affairs. “We will continue to protect public health by carefully monitoring the provisions of this injunction. FDA will also continue to investigate and take action against other marketers of unapproved drugs.”

    In June 2006, FDA issued a guidance document entitled “Marketed Unapproved Drugs–Compliance Policy Guide” (CPG). The CPG makes clear that firms may not market drugs that require approval without first establishing in applications that the products are safe and effective. One of the priorities in this CPG is enforcement actions against manufacturers that violate other provisions of the Federal Food, Drug, and Cosmetic Act.

    For more information:
    FDA’s ongoing efforts on marketing unapproved drugs
    www.fda.gov/cder/drug/unapproved_drugs

    CDER’s web page on Compliance with Current Good Manufacturing Practices
    www.fda.gov/cder/dmpq/

April 27, 2007 — KRIFTEL, GERMANY — The basan Group, a leading distributor of cleanroom products and services in Europe and Asia, has agreed to acquire certain assets from Metron Technology, Inc., constituting Metron’s Europe and Southeast Asia cleanroom consumables and garment manufacturing business. This acquisition will significantly expand basan’s capabilities to provide high-value cleanroom equipment and consumables as well as cleanroom supply management and personnel training capabilities worldwide.

Under terms of the agreement, basan will assume the operations of Metron’s cleanroom consumables operations in Belgium, Germany, France, Ireland, Italy, Malaysia, the Netherlands, Singapore, and UK. basan will also acquire a cleanroom garment production plant from Metron in Malaysia.

In countries where basan has exisiting business activities, Metron’s cleanroom consumables business will be integrated as part its ongoing operations. In markets that are new for basan, branch offices are being established. A complete infrastructure integration plan will be implemented in the coming months.

basan has distributed cleanroom products and services for 25 years and has a portfolio of over 4,000 high-quality, economical cleanroom products, ranging from cleanroom consumables, such as wipers, gloves, stationery, packaging material, disposable and reusable garments, as well as floorings, equipment, and furniture. basan’s full service offerings include consultancy and service offerings such as training of personnel, symposia, garment programs, logistics services, and complete system integration.

In the logistics area, basan ensures the permanent availability of defined cleanroom consumables and assumes all administrative and logistic functions, including consumption planning, local inventory management, and material and transport arrangements.

The acquisition of Metron’s Europe and Southeast Asia cleanroom consumables and garment manufacturing business is expected to close by the end of the month. At this time, basan expects to have 114 employees. The group’s central office will remain in Kriftel, Germany.

Contact:
Christiane Schwittay, basan
+49 6192 9986-0
[email protected]

FDA News
Consumer Inquiries: 888-INFO-FDA

April 28, 2007 — /FDA News/ — The U.S. Department of Agriculture (USDA) and the U.S. Food and Drug Administration (FDA) continue their investigation of imported rice protein concentrate which has been found to contain melamine and melamine-related compounds. Based on information currently available, FDA and USDA believe the likelihood of illness after eating pork from swine fed the contaminated product would be very low. The agencies are taking certain actions out of an abundance of caution. As announced on April 26, swine known to have been fed adulterated (contaminated) product will not be approved to enter the food supply. (Because the animal feed in question was adulterated, USDA cannot rule out the possibility that food produced from animals fed this product could also be adulterated. USDA cannot approve potentially adulterated meat.) This update provides additional information regarding the ongoing investigation.

As reported on April 22 by FDA, the Agency determined that rice protein concentrate imported from China was contaminated with melamine and melamine-related compounds. The product was imported by Wilbur-Ellis, an importer and distributor of agricultural products. Although the company began importing product from China in August 2006, the company did not become aware of the contamination until April 2007. As part of the ongoing investigation, FDA has determined the rice protein was used in the production of pet food and a portion of the pet food was used to produce animal feed. The ongoing investigation is tracing products distributed since August 2006 by Wilbur-Ellis throughout the distribution chain.

At this time, we have no evidence of harm to humans associated with the processed pork product, and therefore no recall of meat products processed from these animals is being issued. Testing and the joint investigation continue. If any evidence surfaces to indicate there is harm to humans, the appropriate action will be taken.

The assessment that, if there were to be harm to human health, it would be very low, is based on a number of factors, including the dilution of the contaminating melamine and melamine-related compounds from the original rice protein concentrate as it moves through the food system. First it is a partial ingredient in the pet food; second, it is only part of the total feed given to the hogs; third, it is not known to accumulate in the hogs and the hogs excrete melamine in their urine; fourth, even if present in pork, pork is only a small part of the average American diet. Neither FDA nor USDA has uncovered any evidence of harm to the swine from the contaminated feed. In addition to the dilutional factor and the lack of evidence of illnesses in the swine fed the waste pet food, we are not aware of any human illness that has occurred from exposure to melamine or its by-products. While the Centers for Disease Control and Prevention systems would have limited ability to detect subtle problems due to melamine and melamine-related compounds, no problems have been detected to date. To further evaluate any potential harm to humans, the FDA is developing and implementing further tests and risk assessments based on the toxicity of the compounds and how much of the compounds consumers could be expected to actually consume.

The ongoing investigation and product reconciliation and testing have led to certain farms. We expect the investigation will continue to find more places where product may have been distributed. As of April 26, sites in the following states are believed to have received and used contaminated product: California, Kansas, New York, North Carolina, South Carolina and Utah. As we confirm additional sites that have received and used contaminated product, we will provide additional updates. USDA and FDA continue to conduct a full, comprehensive examination to protect the nation’s food supply and will provide updates as new information is confirmed.

Air Products is now the largest industrial gas supplier in Poland

April 30, 2007 — /PRNewswire-FirstCall/ — LEHIGH VALLEY, PA — Air Products announced today that it has completed the acquisition of the industrial gas business of BOC Gazy Sp z o.o. from The Linde Group for 370 million euros or about $503 million. With this transaction, Air Products is now the leading industrial gas supplier in Central Europe’s fastest growing economy.

Air Products announced on January 8 its intention to acquire the BOC Gazy business and has since received clearance from the European and Polish regulatory authorities.

“This is a very compelling investment for Air Products,” said John McGlade, president and chief operating officer. “We now have the assets, infrastructure, people and management talent to take full advantage of the opportunities that come from having the leading position in one of the world’s fastest growing economies. Poland is the fourth largest recipient of foreign direct investment next to China, India, and Brazil. Our combined operations are in the industrial heartland of the region where we can bring new applications and technology to drive quality, efficiency, and performance in our customers’ businesses.”

The business, headquartered in Warsaw, has approximately 750 employees, five major industrial gas plants, and six cylinder transfill facilities serving customers across a diverse range of industries, including chemicals, steel, and base metals, among others. Combined with Air Products’ existing Polish business, 2006 sales were about 140 million euros or about $190 million.

Air Products operates in 15 countries throughout Europe, including the central and eastern European countries of the Slovak Republic, the Czech Republic, Russia, and Poland. Total European sales in Air Products’ 2006 fiscal year were approximately $2.6 billion.

Air Products serves customers in industrial, energy, technology, and healthcare markets worldwide with a unique portfolio of atmospheric gases, process and specialty gases, performance materials, and equipment and services. Founded in 1940, Air Products has built leading positions in key growth markets such as semiconductor materials, refinery hydrogen, home healthcare services, natural gas liquefaction, and advanced coatings and adhesives. The company is recognized for its innovative culture, operational excellence and commitment to safety and the environment and is listed in the Dow Jones Sustainability and FTSE4Good Indices. The company has annual revenues of $9 billion, operations in over 40 countries, and over 20,000 employees around the globe. For more information, visit www.airproducts.com.

Source: Air Products

Contact:
Investor inquiries:
Nelson Squires
+1-610-481-7461
[email protected]